The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

ADC Contract Manufacturing Market (4th Edition) by Phase of Development, Type of Component Manufacturing (Antibody, HPAPI / Cytotoxic Payload / Linker, Conjugation, Fill / Finish), Target Indications (Solid Tumors, Hematological Malignancies), Type of Payload Used (Maytansinoid, Auristatin, Pseudomonas Exotoxin, PBD), Type of Linker (SMCC, VC, Hydrazone Linker, Peptide Linker, SPDB), Type of Antibody Origin (Humainzed, Human, Murine, Chimeric), Type of Antibody Isotype and Geography, 2020-2030

  • Lowest Price Guaranteed From USD 5,499

  • Published
    November 2020

  • Pages
    426

  • View Count
    4083

Example Insights

ADC-Contract-Manufacturing-Market-Context ADC-Contract-Manufacturing-Market-Service-Providers ADC-Contract-Manufacturing-Market-Landscape 	ADC-Contract-Manufacturing-Market-key-manufacturing-hubs
ADC-Contract-Manufacturing-Market-Company-Competitiveness-Analysis ADC-Contract-Manufacturing-Market-Recent-Expansions ADC-Contract-Manufacturing-Market-Geographical-Clinical-Research-Landscape ADC-Contract-Manufacturing-Market-Global-Commercial-Demand
	ADC-Contract-Manufacturing-Market-Capacity-Analysis ADC-Contract-Manufacturing-Market-Demand-vs-Supply-Analysis ADC-Contract-Manufacturing-Market-Forecast ADC-Contract-Manufacturing-Market-Opportunity

 

Overview

Since the success of ADCETRIS® (approved in 2011), antibody drug conjugates (ADCs) are now considered a versatile therapeutic tool and have been accepted into the contemporary portfolio of mainstream healthcare solutions. Over time, clinical researchers have been able to further their understanding of the intricacies of ADC design and have also improved the development process of these complex pharmacological interventions. Some of the recently approved ADC therapeutics include BLENREP® (2020), TRODELVYTM (2020), PadcevTM (2019) and POLIVY® (2019). In addition, there are close to 250 unique ADC product candidates under development. Several big pharma players, including AstraZeneca, GlaxoSmithKline, Pfizer, Roche and Takeda, have also acquired stake in this market. Moreover, the fact that companies involved in the development of ADCs, have received over USD 5 billion in capital investments (since 2011), attests to the therapeutic potential and growing popularity of this novel class of targeted therapeutics.  However, the impending growth of the ADC therapeutics market highlights the rising importance of establishing advanced manufacturing capacities in order to meet the anticipated demand. Not all stakeholders in the industry possess end to end capabilities / infrastructure to support the design, development and manufacturing of these complex and highly potent pharmacological entities. 

Owing to the fact that ADCs are highly potent, cytotoxic molecules, the manufacturing of such conjugated entities requires elaborate technical capabilities, along with manufacturing acumen related to both biologics and highly potent chemical substances. Specifically, the development of an antibody requires experience in protein engineering, cell line development, bioprocess development and related scale-up techniques. The production of the cytotoxic payloads, which are used in ADCs, requires contained manufacturing facilities, special equipment, and expertise in advanced chemical synthesis and purification techniques. In addition, the process is incomplete without state-of-art linker technologies, which are required for the final bioconjugation step, wherein the antibody component is attached to the cytotoxic payload. Given the aforementioned requirements, industry stakeholders generally do not (entirely) manufacture ADCs in-house. Presently, it is estimated that, 70-80% of ADC manufacturing operations are outsourced. This trend is likely to persist in the coming years, as well. In fact, even some of the leading players in this domain claim to be dependent on contract manufacturers for the supply of one or more components of their respective ADC products / product candidates. All these factors contribute towards increasing the complexity of ADC supply chain. However, as per the recent industry trends, the number of collaborations, strategic alliances and acquisitions have enabled the companies to offer integrated supply chain solutions. Given the anticipated growth in demand for ADCs, the contract manufacturing market in this domain is anticipated to witness substantial growth in the coming years.

Scope of the Report

The “ADC Contract Manufacturing Market (4th Edition) by Phase of Development (Commercial, Phase III, Phase II and Phase I), Type of Component Manufacturing (Antibody Manufacturing, HPAPI / Cytotoxic Payload and Linker Manufacturing, Conjugation and Fill / Finish), Target Indications (Solid Tumors, Hematological Malignancies and Others), Type of Payload Used (Maytansinoid, Auristatin, Pseudomonas Exotoxin, PBD and Others), Type of Linker Used (SMCC, VC, Hydrazone Linker, Peptide Linker, SPDB, and Others), Type of Antibody Origin (Humainzed, Human, Murine and Chimeric), Type of Antibody Isotype (IgG1, IgG2 and IgG4) and Geography (North America (the US, Canada, Mexico and Rest of North America), Europe (the UK, Germany, France, Spain, Italy and Rest of Europe), Asia-Pacific (Japan, China, Korea, Australia, India, Taiwan and Rest of Asia-Pacific), MENA (Israel, Saudi Arabia, UAE, Egypt), Latin America (Brazil, Peru, Argentina and Rest of Latin America) and Rest of the World), 2020-2030” report offers a comprehensive study of the current scenario and future potential of the ADC contract manufacturing market. The study features an in-depth analysis, highlighting the capabilities of contract services providers engaged in this domain. In addition to other elements, the study includes:

  • An overview of the current market with respect to the players involved in the contract manufacturing of ADCs. It features information on company size, year of establishment, types of services offered (antibody manufacturing / HPAPI or cytotoxic payload manufacturing / linker manufacturing / conjugation / fill-finish), location of headquarters, location of manufacturing facilities, scale of operations (preclinical, clinical and commercial), and additional development services (proof-of-concept studies / process development and scale-up / analytical development). In addition, the chapter includes details on the antibody contract manufacturers and HPAPI / cytotoxic payload contract manufacturers.    
  • Elaborate profiles of contract manufacturers that offer conjugation services at the commercial scale. Each profile provides a brief overview of the company, its financial information, details on ADC manufacturing capabilities, location of facilities, recent developments, and a comprehensive future outlook.
  • A competitiveness analysis of contract manufacturers across key geographical areas, featuring a four-dimensional bubble representation, taking into consideration supplier strength (company size and its experience in this field), service strength (number of ADC services offered, number of additional services offered and location of ADC manufacturing facilities), manufacturing strength (scale of operation and number of ADC manufacturing facilities) and company size (small-sized, mid-sized and large).
  • A detailed analysis of the expansions undertaken (since 2012) by various service providers for augmenting their respective ADC service portfolios, based on a number of parameters, including year of expansion, type of expansion (capacity expansion and new facility), type of service offered (manufacturing services, analytical / development services and fill / finish), geographical location of facility, scale of operation (preclinical, clinical and commercial) and most active players (in terms of number of instances).
  • An analysis of the recent partnerships (since 2012) focused on manufacturing of ADCs, based on various parameters, such as year of agreement, type of agreement (manufacturing agreement, research agreement, product development, licensing agreement, service alliance, acquisition and others), key players and the geographical distribution of this activity.
  • A qualitative analysis highlighting the various factors that need to be taken into consideration by ADC developers, while deciding whether to manufacture their respective products in-house or outsource the manufacturing to a contract service provider.
  • A detailed discussion on various steps of the manufacturing process, namely antibody manufacturing, payload manufacturing, linker manufacturing, conjugation and fill / finish, of an ADC and the cost requirements across each of the aforementioned stages. 
  • An estimate of the overall ADC manufacturing / bioconjugation capacity (in grams / batch) of contract manufacturers based on information provided on their respective websites (wherever available) and additional data collated via secondary and primary research. The analysis highlights the distribution of global capacity by company size (small-sized, mid-sized and large), geographical location of headquarters, geographical location of ADC manufacturing facilities and key players (in terms of highest bioconjugation capacity).
  • An overview of the ADCs that are already approved and those that are under development (clinical and preclinical), featuring information related to their current phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target indication(s), target antigen, antibody origin, antibody isotype, type of payload / warhead, type of linker and key players (in terms of number of preclinical molecules). 
  • A review of the evolution of ADC conjugation technologies, highlighting the various types pf approaches that have been adopted in the past, and the different generations of linkers. It also highlights the competition between contemporary technology platforms.
  • A comprehensive geographical clinical trial analysis of completed, ongoing and planned studies of various ADCs (approved / under development). It provides details related to the different types of antibody isotopes, payloads and linkers investigated / being investigated across various geographies, based on the number of trials registered, trial phase, trial status, target indication, type of sponsor / collaborator, number of patients enrolled and duration of the trials.
  • An informed estimate of the annual demand for ADC products (in grams), taking into account commercial, as well as clinical scale requirements, based on parameters such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.
  • A detailed regional capability assessment framework, which compares the key geographies, based on a number of parameters, such as the number of ADC contract manufacturers, number of ADC manufacturing facilities, number of facility expansions, installed ADC capacity, number of registered clinical trials and demand for ADC’s in that particular geographical region.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall ADC contract manufacturing market.
  • An insightful discussion on the impact of COVID-19 pandemic on the ADC contract manufacturing market. In addition, it features various strategies that different companies have adopted / may adopt in order to mitigate the challenges affiliated to the current global crisis.

One of the key objectives of this report was to evaluate the current opportunity and the future potential of the ADC contract manufacturing market over the coming decade. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] phase of development (commercial, phase III, phase II and phase I), [B] type of component manufacturing (antibody manufacturing, HPAPI / cytotoxic payload and linker manufacturing, conjugation and fill / finish), [C] target indications (solid tumors, hematological malignancies and others), [D] type of payload used (maytansinoid, auristatin, pseudomonas exotoxin, PBD and others), [E] type of linker used (SMCC, VC, hydrazone linker, peptide linker, SPDB, and others), [F] type of antibody origin (humainzed, human, murine and chimeric), [G] type of antibody isotype (IgG1, IgG2 and IgG4) and [H] geography (North America (US, Canada, Mexico and rest of North America), Europe (UK, Germany, France, Spain, Italy and rest of Europe), Asia-Pacific (Japan, China, Korea, Australia, India, Taiwan and rest of Asia-Pacific), MENA (Israel, Saudi Arabia, UAE, Egypt), Latin America (Brazil, Peru, Argentina and rest of Latin America) and rest of the world). To account for the uncertainties associated with the contract manufacturing of ADCs and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were also influenced by discussions held with key stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Aldo Braca (Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciarini (Technical Business Development Manager, BSP Pharmaceuticals)
  • Christian Rohlff (Chief Executive Officer & Founder, Oxford BioTherapeutics)
  • John Burt (Chief Executive Officer, Abzena)
  • Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia)
  • Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma)
  • Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics)
  • Toshimitsu Uenaka (Executive Director, Eisai) and Takashi Owa (Chief Innovation Officer, Eisai)
  • Anthony DeBoer (Director, Business Development, Synaffix)
  • Christian Bailly (Director of CDMO, Pierre Fabre)
  • David Cunningham (Director Corporate Development, Goodwin Biotechnology)
  • Jennifer L. Mitcham (Director, Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)
  • Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza)
  • Mark Wright (Site Head, Piramal Pharma Solutions)
  • Tatsuya Okuzumi (Associate General Manager, Ajinomoto Bio-Pharma Services)
  • Anonymous (Director, Business Development, Leading CMO)
  • Anonymous (Chief Executive Officer, Leading CMO)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading ADC contract manufacturers, across the world?
  • In which regions are majority of the ADC manufacturing facilities located?
  • What percentage of ADC manufacturing operations are outsourced?
  • What are the key regions targeted by contract manufacturers for expansions or new facility set-up?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • What factors are likely to decide if ADC manufacturing should be done in-house or outsourced?
  • What is the overall cost distribution across various steps of ADC manufacturing process?
  • What is overall ADC manufacturing / bioconjugation capacity (in grams / batch) of contract manufacturers?
  • How many ADCs are under development and approved?
  • Which geographies are most active in conducting ADC clinical trials?
  • What is the current, global demand for ADC products?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high level view on the likely evolution of the ADC contract manufacturing market in the mid to long term.

Chapter 3 is a general introduction to ADCs and the manufacturing requirements of such therapeutic products. It includes a detailed discussion on the structure of an ADC and its various components, manufacturing steps and associated challenges. The chapter also provides an overview of the growing trend of contract manufacturing, along with the challenges associated with supply chain and the growing demand for one-stop-shops. Further, it features a discussion on the various parameters that a sponsor company needs to consider while selecting a contract manufacturing partner.

Chapter 4 provides a comprehensive overview of contract manufacturers that are actively involved in the production or conjugation of ADCs. The chapter features information on company size, year of establishment, types of services offered (antibody manufacturing / HPAPI or cytotoxic payload manufacturing / linker manufacturing / conjugation / fill-finish), location of headquarters, location of manufacturing facilities, scale of operations (preclinical, clinical and commercial), and additional development services (proof-of-concept studies / process development and scale-up / anaytical development). The chapter also includes a list of various contract manufacturers offering antibody production services along with the information on the location of their headquarters. Further, it provides a list of HPAPI / cytotoxic payload contract manufacturers along with the information on location of facilities dedicated to the manufacturing of such components.

Chapter 5 features profiles of contract manufacturers that offer conjugation services at the commercial scale. Each profile provides a brief overview of the company, its financial information, details on ADC manufacturing capabilities, location of facilities, recent developments, and a comprehensive future outlook.

Chapter 6 features a detailed comparative analysis of the ADC contract manufacturers. The companies were compared on the basis of various parameters including supplier strength (company size and its experience in this field), service strength (number of ADC services offered, number of additional services offered and location of ADC manufacturing facilities) and manufacturing strength (scale of operation and number of ADC manufacturing facilities).

Chapter 7 highlights the investments made by CMOs to expand or set up new facilities in order to support their ongoing operations. For each such instance, we have provided information on year of expansion, type of expansion (capacity expansion and new facility), type of service offered (manufacturing services, analytical / development services and fill / finish), geographical location of facility, scale of operation (preclinical, clinical and commercial) and most active players (in terms of number of instances).

Chapter 8 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked between different players in this market since 2012. It includes a brief description of the purpose of the partnership models (including research agreements, manufacturing agreements, technology licensing agreements, product development agreements and acquisitions / mergers). Further, it comprises of analysis based on year of agreement, type of agreement, key players and the geographical distribution of this activity.

Chapter 9 presents a qualitative analysis that highlights the various factors that need to be taken into consideration by ADC developers, while deciding whether to manufacture their respective products in-house or outsource the manufacturing to a contract service provider.

Chapter 10 presents a value chain analysis featuring a detailed discussion on the various steps of the ADC manufacturing process, namely antibody manufacturing, payload, linker manufacturing, conjugation and fill / finish and the cost requirements across each of the aforementioned stages.

Chapter 11 features a comprehensive analysis of the overall installed manufacturing / bioconjugation capacity of contract manufacturers and an estimate of the quantity of ADCs that can be produced per batch. The analysis highlights the distribution of global capacity by company size (small-sized, mid-sized and large), geographical location of headquarters, geographical location of ADC manufacturing facilities and key players (in terms of highest bioconjugation capacity).

Chapter 12 provides a comprehensive overview of the market landscape of ADCs that are already approved and those that are under development (clinical and preclinical). This chapter includes information related to their current phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target indication(s), target antigen, antibody origin, antibody isotype, type of payload / warhead, type of linker and key players (in terms of number of preclinical molecules). 

Chapter 13 features an elaborate discussion and competitive analysis of the various ADC conjugation approaches. This chapter also features an overview of the evolution of these technologies, highlighting the competition between contemporary technology platforms.

Chapter 14 features a comprehensive geographical clinical trial analysis of completed, ongoing and planned studies of various ADCs (approved / under development). The analysis provides details related to the types of antibody isotopes, payloads and linkers investigated / being investigated across various geographies, based on the number of trials registered, trial phase, trial status, target indication, type of sponsor / collaborator, number of patients enrolled and duration of the trials.

Chapter 15 features a comprehensive analysis of the annual demand of ADCs (in grams) taking into account commercial, as well as clinical scale requirements. This was based on the parameters such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.

Chapter 16 presents a detailed regional capability assessment framework which compares the key geographies, based on a number of parameters, such as the number of ADC contract manufacturers, number of ADC manufacturing facilities, number of facility expansions, installed ADC capacity, number of registered clinical trials and demand for ADC’s in that particular geographical region.

Chapter 17 presents a comprehensive market forecast analysis, highlighting the likely growth of the contract manufacturing market of ADCs, till 2030. The chapter provides likely distribution of the projected future opportunity based on phase of development (commercial, phase III, phase II and phase I), type of component manufacturing (antibody manufacturing, HPAPI / cytotoxic payload and linker manufacturing, conjugation and fill / finish), target indications (solid tumors, hematological malignancies and others), type of payload used (maytansinoid, auristatin, pseudomonas exotoxin, PBD and others), type of linker used (SMCC, VC, hydrazone linker, peptide linker, SPDB, and others), type of antibody origin (humainzed, human, murine and chimeric), type of antibody isotype (IgG1, IgG2 and IgG4) and geography (North America (US, Canada, Mexico and rest of North America), Europe (UK, Germany, France, Spain, Italy and rest of Europe), Asia-Pacific (Japan, China, Korea, Australia, India, Taiwan and rest of Asia-Pacific), MENA (Israel, Saudi Arabia, UAE, Egypt), Latin America (Brazil, Peru, Argentina and rest of Latin America) and rest of the world(Malia and Chad)). 

Chapter 18 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of ADC contract manufacturing market, under a comprehensive SWOT framework.

Chapter 19 highlights the effect of coronavirus outbreak on the ADC contract manufacturing market. It includes a brief discussion on the short-term and long-term impact of COVID-19 on the supply chain and market opportunity for drug developers and contract manufacturers. In addition, it includes a brief section on strategies and action plans that pharma companies are likely to adopt in order to prepare for supply chain disruptions in future.

Chapter 20 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 21 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with  Aldo Braca (Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciar ini (Technical Business Development Manager, BSP Pharmaceuticals), Christian Rohlff (Chief Executive Officer & Founder, Oxford BioTherapeutics), John Burt (Chief Executive Officer, Abzena), Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia), Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma), Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics), Toshimitsu Uenaka (Executive Director, Eisai) and Takashi Owa (Chief Innovation Officer, Eisai), Anthony DeBoer (Director, Business Development, Synaffix), Christian Bailly (Director of CDMO, Pierre Fabre), David Cunningham (Director Corporate Development, Goodwin Biotechnology), Jennifer L. Mitcham (Director,  Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions), Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza), Mark Wright (Site Head, Piramal Pharma Solutions), Tatsuya Okuzumi (Associate General Manager, Ajinomoto Bio-Pharma Services), Anonymous (Director, Business Development, Leading CMO) and Anonymous (Chief Executive Officer, Leading CMO).

Chapter 22 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 23 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4 Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview

3.2. Key Components of Antibody Drug Conjugates (ADCs)
3.2.1. Antibody
3.2.2. Cytotoxin
3.2.3. Linker

3.3. ADC Manufacturing
3.3.1. Key Steps
3.3.2. Technical Challenges
3.3.3. Need for Outsourcing

3.4. Challenges Associated with Supply Chain and Method Transfer
3.4.1. Growing Demand for One-Stop-Shops and Integrated Service Providers

3.5. Selecting a CMO Partner

4. ADC CONTRACT MANUFACTURING SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. ADC Contract Manufacturing Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Service(s) Offered
4.2.4. Analysis by Other ADC Services Offered
4.2.5. Analysis by Scale of Operation
4.2.6. Analysis by Location of Headquarters
4.2.7. Analysis by Location of Manufacturing Facility

4.3. List of Antibody Contract Manufacturing Service Providers
4.4. List of HPAPI / Cytotoxic Drug Contract Manufacturing Service Providers

5. COMPANY PROFILES
5.1. Chapter Overview

5.2. AbbVie Contract Manufacturing
5.2.1. Company Overview and Financial Information
5.2.2. ADC Offerings
5.2.3. Manufacturing Facilities
5.2.4. Recent Developments
5.2.5. Future Outlook

5.3. ADC Biotechnology
5.3.1. Company Overview and Financial Information
5.3.2. ADC Offerings
5.3.3. Manufacturing Facilities
5.3.4. Recent Developments
5.3.5. Future Outlook

5.4. Ajinomoto Bio-Pharma Services
5.4.1. Company Overview and Financial Information
5.4.2. ADC Offerings
5.4.3. Manufacturing Facilities
5.4.4. Recent Developments
5.4.5. Future Outlook

5.5. BOC Sciences
5.5.1. Company Overview and Financial Information
5.5.2. ADC Offerings
5.5.3. Manufacturing Facilities
5.5.4. Recent Developments
5.5.5. Future Outlook

5.6. BSP Pharmaceuticals
5.6.1. Company Overview
5.6.2. ADC Offerings
5.6.3. Manufacturing Facilities
5.6.5. Future Outlook

5.7. CARBOGEN AMCIS
5.7.1. Company Overview
5.7.2. ADC Offerings
5.7.3. Manufacturing Facilities
5.7.4. Recent Developments
5.7.5. Future Outlook

5.8. Cerbios-Pharma
5.8.1. Company Overview
5.8.2. ADC Offerings
5.8.3. Manufacturing Facilities
5.8.4. Recent Developments
5.8.5. Future Outlook

5.9. Creative Biolabs
5.9.1. Company Overview
5.9.2. ADC Offerings
5.9.3. Manufacturing Facilities
5.9.4. Recent Developments
5.9.5. Future Outlook

5.10. Goodwin Biotechnology
5.10.1. Company Overview
5.10.2. ADC Offerings
5.10.3. Manufacturing Facilities
5.10.4. Recent Developments
5.10.5. Future Outlook

5.11. Lonza
5.11.1. Company Overview and Financial Information
5.11.2. ADC Offerings
5.11.3. Manufacturing Facilities
5.11.4. Recent Developments
5.11.5. Future Outlook

5.12. MabPlex
5.12.1. Company Overview
5.12.2. ADC Offerings
5.12.3. Manufacturing Facilities
5.12.4. Recent Developments
5.12.5. Future Outlook

5.13. Millipore Sigma
5.13.1. Company Overview
5.13.2. ADC Offerings
5.13.3. Manufacturing Facilities
5.13.4. Recent Developments
5.13.5. Future Outlook

5.14. Novasep
5.14.1. Company Overview
5.14.2. ADC Offerings
5.14.3. Manufacturing Facilities
5.14.4. Future Outlook

5.15. Pierre Fabre
5.15.1. Company Overview and Financial Information
5.15.2. ADC Offerings
5.15.3. Manufacturing Facilities
5.15.4. Recent Developments
5.15.5. Future Outlook

5.16. Piramal Pharma Solutions
5.16.1. Company Overview and Financial Information
5.16.2. ADC Offerings
5.16.3. Manufacturing Facilities
5.16.4. Recent Developments
5.16.5. Future Outlook

5.17. WuXi Biologics
5.17.1. Company Overview and Financial Information
5.17.2. ADC Offerings
5.17.3. Manufacturing Facilities
5.17.4. Recent Developments
5.17.5. Future Outlook

6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology and Key Parameters
6.3. ADC Contract Manufacturing Service Providers
6.3.1. ADC Contract Manufacturing Service Providers based in North America
6.3.2. ADC Contract Manufacturing Service Providers based in Europe
6.3.3. ADC Contract Manufacturing Service Providers based in Asia-Pacific and Rest of the World

7. ADC CONTRACT MANUFACTURING SERVICE PROVIDERS: RECENT EXPANSIONS
7.1. Chapter Overview
7.2. ADC Contract Manufacturing Service Providers: Recent Expansions
7.2.1. Analysis by Year of Expansion
7.2.2. Analysis by Type of Expansion
7.2.3. Analysis by Type of Service(s) Offered
7.2.4. Analysis by Location of Expanded Facility
7.2.5. Analysis by Scale of Operation
7.2.6. Most Active Players: Analysis by Number of Expansions

8. ADC CONTRACT MANUFACTURING SERVICE PROVIDERS: PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. ADC Contract Manufacturing Service Providers: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Most Active Players: Analysis by Number of Partnerships
8.3.4. Regional Analysis
8.3.4.1. Most Active Players
8.3.4.2. Intercontinental and Intracontinental Agreements

9. MAKE VERSUS BUY DECISION MAKING
9.1. Chapter Overview
9.2. Assumptions and Parameter Definitions
9.2.1. Scenario 1
9.2.2. Scenario 2
9.2.3. Scenario 3
9.2.4. Scenario 4
9.3. Concluding Remarks

10. VALUE CHAIN ANALYSIS
10.1. Chapter Overview
10.2. ADC Development Value Chain
10.3. Cost Distribution Across the Value Chain
10.3.1. Cost Associated with Antibody Manufacturing
10.3.2. Cost Associated with Payload and Linker Manufacturing
10.3.3. Cost Associated with Conjugation
10.3.4. Cost Associated with Fill / Finish

11. ADC MANUFACTURING: CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. ADC Manufacturing: Global Installed Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Location of Headquarters
11.3.3. Analysis by Location of Manufacturing Facilities
11.3.3.1 By Country
11.3.3.2. By Continent
11.3.4. Analysis by Key Players

12. ADC THERAPEUTICS: MARKET OVERVIEW
12.1. Chapter Overview
12.2. ADC Therapeutics: Clinical Pipeline
12.2.1. Analysis by Phase of Development
12.2.2. Analysis by Target Indication
12.2.3. Analysis by Target Antigen
12.2.4. Analysis by Antibody Origin
12.2.5. Analysis by Type of Antibody Isotype
12.2.6. Analysis by Payload Type
12.2.7. Analysis by Linker Type

12.3. ADC Therapeutics: Preclinical / Discovery Pipeline
12.3.1. Key Technology Providers: Analysis by Number of ADC Therapeutics

13. NOVEL ADC CONJUGATION TECHNOLOGY PLATFORMS
13.1. Chapter Overview
13.2. First Generation ADC Technologies

13.3. Second Generation ADC Technologies
13.3.1. Cysteine and Selenocysteine Engineering
13.3.2. Unnatural Amino Acid Engineering
13.3.3. Amino-Terminal Serine Engineering

13.4. Third Generation ADC Technologies
13.4.1. Enzyme-Assisted Ligation Approaches
13.4.2. Glycan Remodeling Approaches
13.4.3. Ligation at Fab Nucleotide-Binding Site
13.4.4. Cysteine Re-bridging
13.4.5. Avoiding or Limiting Retro-Michael Drug Deconjugation
13.5. Evolutionary Analysis

14. GEOGRAPHICAL CLINICAL TRIALS ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. ADC Therapeutics: Overall Clinical Trial Analysis
14.3.1. Analysis by Trial Registration Year
14.3.2. Analysis by Trial Phase
14.3.3. Analysis by Trial Status
14.3.4. Analysis by Type of Sponsor / Collaborator
14.3.5. Analysis by Type of Cancer
14.3.6. Most Active Players: Analysis by Number of Clinical Trials
14.3.7. Geographical Analysis by Number of Clinical Trials
14.3.8. Geographical Analysis by Enrolled Patient Population

14.4. ADC Therapeutics: Geographical Clinical Trial Analysis by Antibody Isotope
14.4.1. IgG1 based Molecules
14.4.1.1. Geographical Analysis by Trial Phase
14.4.1.2. Geographical Analysis by Trial Status
14.4.1.3. Geographical Analysis by Enrolled Patient Population
14.4.1.4. Analysis by Duration of Clinical Trials

14.4.2. IgG2 based Molecules
14.4.2.1. Geographical Analysis by Trial Phase
14.4.2.2. Geographical Analysis by Trial Status
14.4.2.3. Geographical Analysis by Enrolled Patient Population
14.4.2.4. Analysis by Duration of Clinical Trials

14.4.3. IgG4 based Molecules
14.4.3.1. Geographical Analysis by Trial Phase
14.4.3.2. Geographical Analysis by Trial Status
14.4.3.3. Geographical Analysis by Enrolled Patient Population
14.4.3.4. Analysis by Duration of Clinical Trials

14.5. ADC Therapeutics: Geographical Clinical Trial Analysis by Payload Type
14.5.1. Auristatin based Molecules
14.5.1.1. Geographical Analysis by Trial Phase
14.5.1.2. Geographical Analysis by Trial Status
14.5.1.3. Geographical Analysis by Enrolled Patient Population
14.5.1.4. Analysis by Duration of Clinical Trials

14.5.2. Maytansinoid based Molecules
14.5.2.1. Geographical Analysis by Trial Phase
14.5.2.2. Geographical Analysis by Trial Status
14.5.2.3. Geographical Analysis by Enrolled Patient Population
14.5.2.4. Analysis by Duration of Clinical Trials

14.5.3. Calicheamicin based Molecules
14.5.3.1. Geographical Analysis by Trial Phase
14.5.3.2. Geographical Analysis by Trial Status
14.5.3.3. Geographical Analysis by Enrolled Patient Population
14.5.3.4. Analysis by Duration of Clinical Trials

14.5.4. PBD based Molecules
14.5.4.1. Geographical Analysis by Trial Phase
14.5.4.2. Geographical Analysis by Trial Status
14.5.4.3. Geographical Analysis by Enrolled Patient Population
14.5.4.4. Analysis by Duration of Clinical Trials

14.5.5. Camptothecin based Molecules
14.5.5.1. Geographical Analysis by Trial Phase
14.5.5.2. Geographical Analysis by Trial Status
14.5.5.3. Geographical Analysis by Enrolled Patient Population
14.5.5.4. Analysis by Duration of Clinical Trials

14.5.6. Pyranoindolizinoquinoline based Molecules
14.5.6.1. Geographical Analysis by Trial Phase
14.5.6.2. Geographical Analysis by Trial Status
14.5.6.3. Geographical Analysis by Enrolled Patient Population
14.5.6.4. Analysis by Duration of Clinical Trials

14.5.7. Other Payload based Molecules
14.5.7.1. Geographical Analysis by Trial Phase
14.5.7.2. Geographical Analysis by Trial Status
14.5.7.3. Geographical Analysis by Enrolled Patient Population
14.5.7.4. Analysis by Duration of Clinical Trials

14.6. ADC Therapeutics: Geographical Clinical Trial Analysis by Linker Type
14.6.1. VC based Molecules
14.6.1.1. Geographical Analysis by Trial Phase
14.6.1.2. Geographical Analysis by Trial Status
14.6.1.3. Geographical Analysis by Enrolled Patient Population
14.6.1.4. Analysis by Duration of Clinical Trials

14.6.2. Hydrazone Linker based Molecules
14.6.2.1. Geographical Analysis by Trial Phase
14.6.2.2. Geographical Analysis by Trial Status
14.6.2.3. Geographical Analysis by Enrolled Patient Population
14.6.2.4. Analysis by Duration of Clinical Trials

14.6.3. SMCC based Molecules
14.6.3.1. Geographical Analysis by Trial Phase
14.6.3.2. Geographical Analysis by Trial Status
14.6.3.3. Geographical Analysis by Enrolled Patient Population
14.6.3.4. Analysis by Duration of Clinical Trials

14.6.4. Peptide Linker based Molecules
14.6.4.1. Geographical Analysis by Trial Phase
14.6.4.2. Geographical Analysis by Trial Status
14.6.4.3. Geographical Analysis by Enrolled Patient Population
14.6.4.4. Analysis by Duration of Clinical Trials

14.6.5. SPDB based Molecules
14.6.5.1. Geographical Analysis by Trial Phase
14.6.5.2. Geographical Analysis by Trial Status
14.6.5.3. Geographical Analysis by Enrolled Patient Population
14.6.5.4. Analysis by Duration of Clinical Trials

14.6.6. MC based Molecules
14.6.6.1. Geographical Analysis by Trial Phase
14.6.6.2. Geographical Analysis by Trial Status
14.6.6.3. Geographical Analysis by Enrolled Patient Population
14.6.6.4. Analysis by Duration of Clinical Trials

14.6.7. Others Type Linker based Molecules
14.6.7.1. Geographical Analysis by Trial Phase
14.6.7.2. Geographical Analysis by Trial Status
14.6.7.3. Geographical Analysis by Enrolled Patient Population
14.6.7.4. Analysis by Duration of Clinical Trials

15. ADC THERAPEUTICS: DEMAND ANALYSIS
15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. ADC Therapeutics: Overall Annual Demand
15.3.1. ADC Therapeutics: Annual Commercial Demand
15.3.1.1. Analysis by Type of Cancer
15.3.1.2. Analysis by Antibody Origin
15.3.1.3. Analysis by Type of Antibody Isotype
15.3.1.4. Analysis by Payload Type
15.3.1.5. Analysis by Linker Type

15.3.2. ADC Therapeutics: Annual Clinical Demand
15.3.2.1. Analysis by Phase of Development
15.3.2.2. Analysis by Type of Cancer
15.3.2.3. Analysis by Antibody Origin
15.3.2.4. Analysis by Type of Antibody Isotype
15.3.2.5. Analysis by Payload Type
15.3.2.6. Analysis by Linker Type
15.3.2.7. Analysis by Key Geographical Regions

15.4. ADC Therapeutics: Demand and Supply Analysis

16. REGIONAL CAPABILITY ASSESSMENT ANALYSIS
16.1. Chapter Overview
16.2. Assumptions and Key Parameters
16.3. Regional Capability Assessment in North America
16.4. Regional Capability Assessment in Europe
16.5. Regional Capability Assessment in Asia-Pacific Region

17. MARKET SIZING AND OPPORTUNITY ANALYSIS
17.1. Chapter Overview
17.2. Forecast Methodology
17.3. Overall ADC Therapeutics Market, 2020-2030
17.4. Input Data and Key Assumptions

17.5. Overall ADC Contract Manufacturing Market, 2020-2030
17.5.1. ADC Contract Manufacturing Market, 2020-2030: Distribution by Type of Component Manufacturing
17.5.2. ADC Contract Manufacturing Market, 2020-2030: Distribution by Phase of Development

17.6. ADC Contract Manufacturing Market for Commercial Products, 2020-2030
17.6.1. ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Type of Component Manufacturing
17.6.2. ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Type of Cancer
17.6.3. ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Antibody Origin
17.6.4. ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Type of Antibody Isotype
17.6.5. ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Payload Type
17.6.6. ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Linker Type

17.6.7. ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Key Geographical Regions
17.6.7.1. ADC Contract Manufacturing Market for Commercial Products in North America, 2020-2030
17.6.7.2. ADC Contract Manufacturing Market for Commercial Products in EU5, 2020-2030
17.6.7.2. ADC Contract Manufacturing Market for Commercial Products in Rest of the World, 2020-2030

17.7. ADC Contract Manufacturing Market for Clinical Products, 2020-2030
17.7.1. ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Type of Component Manufacturing
17.7.2. ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Type of Cancer
17.7.3. ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Antibody Origin
17.7.4. ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Type of Antibody Isotype
17.7.5. ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Payload Type
17.7.6. ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Linker Type

17.7.7. ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Key Geographical Regions
17.7.7.1. ADC Contract Manufacturing Market for Clinical Products in North America, 2020-2030
17.7.7.2. ADC Contract Manufacturing Market for Clinical Products in Europe, 2020-2030
17.7.7.3. ADC Contract Manufacturing Market for Clinical Products in Asia-Pacific, 2020-2030
17.7.7.4. ADC Contract Manufacturing Market for Clinical Products in MENA, 2020-2030
17.7.7.5. ADC Contract Manufacturing Market for Clinical Products in Latin America, 2020-2030
17.7.7.6. ADC Contract Manufacturing Market for Clinical Products in Rest of the World, 2020-2030

18. SWOT ANALYSIS
18.1. Chapter Overview
18.1.1. Strengths
18.1.2. Weaknesses
18.1.3. Opportunities
18.1.4. Threats

19. IMPACT OF COVID-19 PANDEMIC ON THE ADC CONTRACT MANUFACTURING MARKET
19.1 Chapter Overview
19.2. Current Opinions and Recuperative Initiatives of Key Players
19.2.1. ADC Biotechnology
19.2.2. Ajinomoto Bio-Pharma Services
19.2.3. CARBOGEN AMCIS
19.2.4. Goodwin Biotechnology
19.2.5. Lonza
19.2.6. Millipore Sigma
19.2.7. Novasep
19.2.8. Pierre Fabre
19.2.9. Piramal Pharma Solutions
19.2.10. Wuxi Biologics

19.3. Impact on ADC Contract Manufacturing Market
19.4. Recuperative Strategies for Contract Service Providers
19.4.1. Strategies for Implementation in the Short / Mid Term
19.4.2. Strategies for Implementation in the Long Term

20. CONCLUDING REMARKS
20.1. Chapter Overview

21. INTERVIEW TRANSCRIPTS
21.1. Chapter Overview
21.2. BSP Pharmaceuticals
21.2.1. Company Snapshot
21.2.2. Interview Transcript: Aldo Braca, Chief Executive Officer and Giorgio Salciarini, Technical Business Development Manager

21.3. Oxford BioTherapeutics
21.3.1. Company Snapshot
21.3.2. Interview Transcript: Christian Rohlff, Chief Executive Officer & Founder

21.4. Abzena
21.4.1. Company Snapshot
21.4.2. Interview Transcript: John Burt, Chief Executive Officer

21.5. Syndivia
21.5.1. Company Snapshot
21.5.2. Interview Transcript: Sasha Koniev, Chief Executive Officer & Co-Founder

21.6. Cerbios-Pharma
21.6.1. Company Snapshot
21.6.2. Interview Transcript: Denis Angioletti, Chief Commercial Officer

21.7. NBE-Therapeutics
21.7.1. Company Snapshot
21.7.2. Interview Transcript: Wouter Verhoeven, Chief Business Officer

21.8. Eisai
21.8.1. Company Snapshot
21.8.2. Interview Transcript: Toshimitsu Uenaka, Executive Director and Takashi Owa, Chief Innovation Officer

21.9. Synaffix
21.9.1. Company Snapshot
21.9.2. Interview Transcript: Anthony DeBoer, Director, Business Development

21.10. Pierre Fabre
21.10.1. Company Snapshot
21.10.2. Interview Transcript: Christian Bailly, Director of CDMO

21.11. Goodwin Biotechnology
21.11.1. Company Snapshot
21.11.2. Interview Transcript: David Cunningham, Director Corporate Development

21.12. Catalent Pharma Solutions
21.12.1. Company Snapshot
21.12.2. Interview Transcript: Jennifer L. Mitcham, Director, Business Development and Stacy McDonald, Group Product Manager

21.13. Lonza
21.13.1. Company Snapshot
21.13.2. Interview Transcript: Laurent Ducry, Head of Bioconjugates Commercial Development

21.14. Piramal Pharma Solutions
21.14.1. Company Snapshot
21.14.2. Interview Transcript: Mark Wright, Site Head

21.15. Ajinomoto Bio-Pharma Services
21.15.1. Company Snapshot
21.15.2. Interview Transcript: Tatsuya Okuzumi, Associate General Manager

21.16. Anonymous, Director, Business Development, Leading CMO
21.17. Anonymous, Chief Executive Officer, Leading CMO

22. APPENDIX 1: TABULATED DATA

23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Key Components of an Antibody Drug Conjugate
Figure 3.2 ADC Manufacturing Steps
Figure 4.1 ADC Contract Manufacturing Service Providers: Distribution by Year of Establishment
Figure 4.2 ADC Contract Manufacturing Service Providers: Distribution by Company Size
Figure 4.3 ADC Contract Manufacturing Service Providers: Distribution by Service(s) Offered
Figure 4.4 ADC Contract Manufacturing Service Providers: Distribution by Other Service(s) Offered
Figure 4.5 ADC Contract Manufacturing Service Providers: Distribution by Scale of Operation
Figure 4.6 ADC Contract Manufacturing Service Providers: Distribution by Location of Headquarters
Figure 4.7 ADC Contract Manufacturing Service Providers: Distribution by Service(s) Offered and Location of Headquarters
Figure 4.8 ADC Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facilities
Figure 6.1 Company Competitiveness Analysis: ADC Contract Manufacturing Service Providers based in North America
Figure 6.2 Company Competitiveness Analysis: ADC Contract Manufacturing Service Providers based in Europe
Figure 6.3 Company Competitiveness Analysis: ADC Contract Manufacturing Service Providers based in Asia-Pacific
Figure 7.1 Recent Expansions: Cumulative Year-wise Trend, 2012-2020
Figure 7.2 Recent Expansions: Distribution by Type of Facility Expansion
Figure 7.3 Recent Expansions: Distribution by Type of Service(s) Offered
Figure 7.4 Recent Expansions: Distribution by Year of Expansion and Type of Service(s) Offered
Figure 7.5 Recent Expansions: Distribution by Location of Expanded Facility
Figure 7.6 Recent Expansions: Distribution by Scale of Operation
Figure 7.7 Recent Expansions: Distribution by Location of Expanded Facility and Scale of Operation
Figure 7.8 Most Active Players: Distribution by Number of Expansions
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2012-2020
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Most Active Players: Distribution by Number of Partnerships
Figure 8.4 Partnerships and Collaborations: Regional Distribution
Figure 8.5 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 9.1 Make versus Buy Decision Making Framework
Figure 10.1 Value Chain Analysis: ADC Development Overview
Figure 10.2 ADC Contract Manufacturing Value Chain Overview
Figure 10.3 ADC Therapeutics: Distribution by Cost of Raw Material Required for Clinical Stage Manufacturing (%)
Figure 10.4 Value Chain Analysis: Distribution by Cost
Figure 10.5 Costs Associated with Antibody Manufacturing
Figure 10.6 Costs Associated with Payload and Linker Manufacturing
Figure 10.7 Costs Associated with Conjugation
Figure 10.8 Costs Associated with Fill / Finish
Figure 11.1 Capacity Analysis: Distribution by Company Size
Figure 11.2 Capacity Analysis: Distribution by Location of Headquarters
Figure 11.3 Capacity Analysis: Distribution by Location of Manufacturing Facilities (Country-wise)
Figure 11.4 Capacity Analysis: Distribution by Location of Manufacturing Facilities (Continent-wise)
Figure 11.5 Overall ADC Installed Manufacturing Capacity: Distribution by Key Players
Figure 12.1 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Phase of Development
Figure 12.2 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Target Indication
Figure 12.3 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Type of Solid Tumor
Figure 12.4 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Type of Hematological Malignancies
Figure 12.5 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Target Antigen
Figure 12.6 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Antibody Origin
Figure 12.7 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Antibody Isotype
Figure 12.8 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Type of Payload / Warhead
Figure 12.9 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Type of Linker
Figure 12.10 ADC Therapeutics (Preclinical Pipeline): Distribution by Key Technology Providers
Figure 13.1 ADC Conjugation Platforms: Technological Evolution
Figure 13.2 ADC Conjugation Platforms: Technology Landscape
Figure 14.1 Clinical Trial Analysis: Distribution by Trial Registration Year
Figure 14.2 Clinical Trial Analysis: Distribution by Trial Phase
Figure 14.3 Clinical Trial Analysis: Distribution by Trial Status
Figure 14.4 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 14.5 Clinical Trial Analysis: Distribution by Type of Cancer
Figure 14.6 Most Active Industry Players: Distribution by Number of Registered Studies
Figure 14.7 Geographical Clinical Trial Analysis: Distribution by Number of Trials
Figure 14.8 Geographical Clinical Trial Analysis: Distribution by Enrolled Patient Population
Figure 14.9 Geographical Clinical Trial Analysis: Distribution by Antibody Isotype
Figure 14.10 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Trial Phase
Figure 14.11 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Trial Status
Figure 14.12 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Enrolled Patient Population
Figure 14.13 Geographical Clinical Trial Analysis (IgG2 based Molecules): Distribution by Trial Phase
Figure 14.14 Geographical Clinical Trial Analysis (IgG2 based Molecules): Distribution by Trial Status
Figure 14.15 Geographical Clinical Trial Analysis (IgG2 based Molecules): Distribution by Enrolled Patient Population
Figure 14.16 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Trial Phase
Figure 14.17 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Trial Status
Figure 14.18 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Enrolled Patient Population
Figure 14.19 Geographical Clinical Trial Analysis: Distribution by Payload Type
Figure 14.20 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Trial Phase
Figure 14.21 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Trial Status
Figure 14.22 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Enrolled Patient Population
Figure 14.23 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Trial Phase
Figure 14.24 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Trial Status
Figure 14.25 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Enrolled Patient Population
Figure 14.26 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Trial Phase
Figure 14.27 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Trial Status
Figure 14.28 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Enrolled Patient Population
Figure 14.29 Geographical Clinical Trial Analysis (PBD based Molecules): Distribution by Trial Phase
Figure 14.30 Geographical Clinical Trial Analysis (PBD based Molecules): Distribution by Trial Status
Figure 14.31 Geographical Clinical Trial Analysis (PBD based Molecules): Distribution by Enrolled Patient Population
Figure 14.32 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Trial Phase
Figure 14.33 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Trial Status
Figure 14.34 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Enrolled Patient Population
Figure 14.35 Geographical Clinical Trial Analysis (Pyranoindolizinoquinoline based Molecules): Distribution by Trial Phase
Figure 14.36 Geographical Clinical Trial Analysis (Pyranoindolizinoquinoline based Molecules): Distribution by Trial Status
Figure 14.37 Geographical Clinical Trial Analysis (Pyranoindolizinoquinoline based Molecules): Distribution by Enrolled Patient Population
Figure 14.38 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Trial Phase
Figure 14.39 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Trial Status
Figure 14.40 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Enrolled Patient Population
Figure 14.41 ADC Therapeutics: Geographical Clinical Trial Distribution by Linker Type
Figure 14.42 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Trial Phase
Figure 14.43 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Trial Status
Figure 14.44 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Enrolled Patient Population
Figure 14.45 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Trial Phase
Figure 14.46 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Trial Status
Figure 14.47 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Enrolled Patient Population
Figure 14.48 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Trial Phase
Figure 14.49 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Trial Status
Figure 14.50 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Enrolled Patient Population
Figure 14.51 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Trial Phase
Figure 14.52 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Trial Status
Figure 14.53 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Enrolled Patient Population
Figure 14.54 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Trial Phase
Figure 14.55 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Trial Status
Figure 14.56 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Enrolled Patient Population
Figure 14.57 Geographical Clinical Trial Analysis (MC based Molecules): Distribution by Trial Phase
Figure 14.58 Geographical Clinical Trial Analysis (MC based Molecules): Distribution by Trial Status
Figure 14.59 Geographical Clinical Trial Analysis (MC based Molecules): Distribution by Enrolled Patient Population
Figure 14.60 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Trial Phase
Figure 14.61 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Trial Status
Figure 14.62 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Enrolled Patient Population
Figure 15.1 Global Demand for ADC Therapeutics (in kgs), 2020-2030
Figure 15.2 Global Demand for ADC Therapeutics: Distribution by Scale of Operation, 2020-2030 (in kgs)
Figure 15.3 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Cancer, 2020-2030 (in kgs)
Figure 15.4 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Origin, 2020-2030 (in kgs)
Figure 15.5 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Antibody Isotype, 2020-2030 (in kgs)
Figure 15.6 Global Commercial Demand for ADC Therapeutics: Distribution by Payload Type, 2020-2030 (in kgs)
Figure 15.7 Global Commercial Demand for ADC Therapeutics: Distribution by Linker Type, 2020-2030 (in kgs)
Figure 15.8 Global Clinical Demand for ADC Therapeutics: Distribution by Phase of Development, 2020-2030 (in kgs)
Figure 15.9 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Cancer, 2020-2030 (in kgs)
Figure 15.10 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Origin, 2020-2030 (in kgs)
Figure 15.11 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Isotype, 2020-2030 (in kgs)
Figure 15.12 Global Clinical Demand for ADC Therapeutics: Distribution by Payload Type, 2020-2030 (in kgs)
Figure 15.13 Global Clinical Demand for ADC Therapeutics: Distribution by Linker Type, 2020-2030 (in kgs)
Figure 15.14 Global Clinical Demand for ADC Therapeutics: Distribution by Key Geographical Regions, 2020-2030 (in kgs)
Figure 15.15 ADC Therapeutics: Demand and Supply Scenario, 2020 - 2030
Figure 16.1 Regional Capability Assessment: North America
Figure 16.2 Regional Capability Assessment: Europe
Figure 16.3 Regional Capability Assessment: Asia-Pacific
Figure 17.1 Global ADC Therapeutics Market, 2020-2030 (USD Billion)
Figure 17.2 ADC Therapeutics Market: Relative Cost of Manufacturing by Type of Component Manufacturing
Figure 17.3 ADC Contract Manufacturing Market, 2020-2030: Distribution by Type of Component Manufacturing (USD Million)
Figure 17.4 ADC Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Million)
Figure 17.5 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Type of Component Manufacturing (USD Million)
Figure 17.6 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Type of Cancer (USD Million)
Figure 17.7 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Antibody Origin (USD Million)
Figure 17.8 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Antibody Isotype (USD Million)
Figure 17.9 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Payload Type (USD Million)
Figure 17.10 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Linker Type (USD Million)
Figure 17.11 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Key Geographical Regions (USD Million)
Figure 17.12 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Share of North America (USD Million)
Figure 17.13 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Share of EU5 (USD Million)
Figure 17.14 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Share of Rest of the World (USD Million)
Figure 17.15 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Type of Component Manufacturing (USD Million)
Figure 17.16 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Type of Cancer (USD Million)
Figure 17.17 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Antibody Origin (USD Million)
Figure 17.18 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Antibody Isotype (USD Million)
Figure 17.19 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Payload Type (USD Million)
Figure 17.20 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Linker Type (USD Million)
Figure 17.21 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Key Geographical Regions (USD Million)
Figure 17.22 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Share of North America (USD Million)
Figure 17.23 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Share of Europe (USD Million)
Figure 17.24 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Share of Asia-Pacific (USD Million)
Figure 17.25 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Share of MENA (USD Million)
Figure 17.26 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Share of Latin America (USD Million)
Figure 18.1 SWOT Analysis: Harvey Ball Analysis
Figure 20.1 ADC Contract Manufacturing Market: Conservative, Base and Optimistic Scenario, 2020, 2025 and 2030 (USD Billion)

List Of Tables

Table 3.1 Common Cytotoxins Used for the Production of ADC Therapeutics
Table 3.2 Safebridge / OEL bands for HPAPI / Cytotoxic Payloads
Table 4.1 List of ADC Contract Manufacturing Service Providers
Table 4.2 ADC Contract Manufacturing Service Providers: Information on Service(s) Offered
Table 4.3 ADC Contract Manufacturing Service Providers: Information on Other Service(s) Offered
Table 4.4 ADC Contract Manufacturing Service Providers: Information on Scale of Operation and Available Capacity
Table 4.5 ADC Contract Manufacturing Service Providers: Information on Manufacturing Facilities
Table 4.6 ADC Contract Manufacturing Service Providers: List of Antibody Manufacturing Service Providers
Table 4.7 ADC Contract Manufacturing Service Providers: List of HPAPI and Cytotoxic Drug Manufacturing Service Providers
Table 5.1 AbbVie Contract Manufacturing: Company Overview and Financial Information
Table 5.2 AbbVie Contract Manufacturing: ADC Related Offerings
Table 5.3 AbbVie Contract Manufacturing: Information on Manufacturing Facilities
Table 5.4 AbbVie Contract Manufacturing: Recent Developments
Table 5.5 AbbVie Contract Manufacturing: Future Outlook
Table 5.6 ADC Biotechnology: Company Overview and Financial Information
Table 5.7 ADC Biotechnology: ADC Related Offerings
Table 5.8 ADC Biotechnology: Information on Manufacturing Facilities
Table 5.9 ADC Biotechnology: Recent Developments
Table 5.10 ADC Biotechnology: Future Outlook
Table 5.11 Ajinomoto Bio-Pharma Services: Company Overview
Table 5.12 Ajinomoto Bio-Pharma Services: ADC Related Offerings
Table 5.13 Ajinomoto Bio-Pharma Services: Information on Manufacturing Facilities
Table 5.14 Ajinomoto Bio-Pharma Services: Recent Developments
Table 5.15 Ajinomoto Bio-Pharma Services: Future Outlook
Table 5.16 BOC SCIENCES: Company Overview and Financial Information
Table 5.17 BOC SCIENCES: ADC Related Offerings
Table 5.18 BOC SCIENCES: Information on Manufacturing Facilities
Table 5.19 BOC SCIENCES: Recent Developments
Table 5.20 BSP Pharmaceuticals: Company Overview
Table 5.21 BSP Pharmaceuticals: ADC Related Offerings
Table 5.22 BSP Pharmaceuticals: Information on Manufacturing Facilities
Table 5.23 BSP Pharmaceuticals: Recent Developments
Table 5.24 BSP Pharmaceuticals: Future Outlook
Table 5.25 CARBOGEN AMCIS: Company Overview
Table 5.26 CARBOGEN AMCIS: ADC Related Offerings
Table 5.27 CARBOGEN AMCIS: Information on Manufacturing Facilities
Table 5.28 CARBOGEN AMCIS: Recent Developments
Table 5.29 CARBOGEN AMCIS: Future Outlook
Table 5.30 Cerbios-Pharma: Company Overview
Table 5.31 Cerbios-Pharma: ADC Related Offerings
Table 5.32 Cerbios-Pharma: Information on Manufacturing Facilities
Table 5.33 Cerbios-Pharma: Recent Developments
Table 5.34 Cerbios-Pharma: Future Outlook
Table 5.35 Creative Biolabs: Company Overview
Table 5.36 Creative Biolabs: ADC Related Offerings
Table 5.37 Creative Biolabs: Information on Manufacturing Facilities
Table 5.38 Creative Biolabs: Recent Developments
Table 5.39 Creative Biolabs: Future Outlook
Table 5.40 Goodwin Biotechnology: Company Overview
Table 5.41 Goodwin Biotechnology: ADC Related Offerings
Table 5.42 Goodwin Biotechnology: Information on Manufacturing Facilities
Table 5.43 Goodwin Biotechnology: Recent Developments
Table 5.44 Goodwin Biotechnology: Future Outlook
Table 5.45 Lonza: Company Overview and Financial Information
Table 5.46 Lonza: ADC Related Offerings
Table 5.47 Lonza: Information on Manufacturing Facilities
Table 5.48 Lonza: Recent Developments
Table 5.49 Lonza: Future Outlook
Table 5.50 MabPlex: Company Overview
Table 5.51 MabPlex: ADC Related Offerings
Table 5.52 MabPlex: Information on Manufacturing Facilities
Table 5.53 MabPlex: Recent Developments
Table 5.54 MabPlex: Future Outlook
Table 5.55 Millipore Sigma: Company Overview
Table 5.56 Millipore Sigma: ADC Related Offerings
Table 5.57 Millipore Sigma: Information on Manufacturing Facilities
Table 5.58 Millipore Sigma: Recent Developments
Table 5.59 Millipore Sigma: Future Outlook
Table 5.60 Novasep: Company Overview
Table 5.61 Novasep: ADC Related Offerings
Table 5.62 Novasep: Information on Manufacturing Facilities
Table 5.63 Novasep: Recent Developments
Table 5.64 Novasep: Future Outlook
Table 5.65 Pierre Fabre: Company Overview and Financial Information
Table 5.66 Pierre Fabre: ADC Related Offerings
Table 5.67 Pierre Fabre: Information on Manufacturing Facilities
Table 5.68 Pierre Fabre: Recent Developments
Table 5.69 Pierre Fabre: Future Outlook
Table 5.70 Piramal Pharma Solutions: Company Overview and Financial Information
Table 5.71 Piramal Pharma Solutions: ADC Related Offerings
Table 5.72 Piramal Pharma Solutions: Information on Manufacturing Facilities
Table 5.73 Piramal Pharma Solutions: Recent Developments
Table 5.74 Piramal Pharma Solutions: Future Outlook
Table 5.75 WuXi Biologics: Company Overview and Financial Information
Table 5.76 WuXi Biologics: ADC Related Offerings
Table 5.77 WuXi Biologics: Information on Manufacturing Facilities
Table 5.78 WuXi Biologics: Recent Developments
Table 5.79 WuXi Biologics: Future Outlook
Table 7.1 ADC Contract Manufacturing Service Providers: Recent Facility Expansions, 2012-2020
Table 8.1 ADC Contract Manufacturing Service Providers: Partnerships and Collaborations, 2012-2020
Table 11.1 Installed Global Capacity for ADC Manufacturing: Sample Data Set
Table 11.2 Installed Global Capacity for ADC Manufacturing: Sample Data Set (Average Capacity)
Table 11.3 Installed Global Capacity for ADC Manufacturing: Total Capacity Analysis, based on Company Size
Table 12.1 ADC Therapeutics: Approved / Clinical Stage Candidatesd
Table 12.2 ADC Therapeutics: Clinical Pipeline (Information on Linkers and Payloads)
Table 12.3 ADC Therapeutics: Preclinical / Discovery Pipeline
Table 13.1 Second Generation ADC Technologies: Cysteine and Selenocysteine Engineering
Table 13.2 Second Generation ADC Technologies: Unnatural Amino Acid Engineering
Table 13.3 Second Generation ADC Technologies: Amino-terminal Engineered Serine
Table 13.4 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 13.5 Third Generation ADC Technologies: Glycan Remodeling Approaches
Table 13.6 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 13.7 Third Generation ADC Technologies: Cysteine Rebridging
Table 13.8 Third Generation ADC Technologies: Avoiding or Limiting Retro-Michael Drug Deconjugation
Table 14.1 Geographical Clinical Trial Analysis (IgG1 based Molecules): Duration of Trials
Table 14.2 Geographical Clinical Trial Analysis (IgG2 based Molecules): Duration of Trials
Table 14.3 Geographical Clinical Trial Analysis (IgG4 based Molecules): Duration of Trials
Table 14.4 Geographical Clinical Trial Analysis (Auristatin based Molecules): Duration of Trials
Table 14.5 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Duration of Trials
Table 14.6 Geographical Clinical Trial Analysis (Calicheamicin Based Molecules): Duration of Trials
Table 14.7 Geographical Clinical Trial Analysis (PBD based Molecules): Duration of Trials
Table 14.8 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Duration of Trials
Table 14.9 Geographical Clinical Trial Analysis (Pyranoindolizinoquinoline Based Molecules): Duration of Trials
Table 14.10 Geographical Clinical Trial Analysis (Other Payload based Molecules): Duration of Trials
Table 14.11 Geographical Clinical Trial Analysis (VC based Molecules): Duration of Trials
Table 14.12 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Duration of Trials
Table 14.13 Geographical Clinical Trial Analysis (SMCC based Molecules): Duration of Trials
Table 14.14 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Duration of Trials
Table 14.15 Geographical Clinical Trial Analysis (SPDB based Molecules): Duration of Trials
Table 14.16 Geographical Clinical Trial Analysis (MC based Molecules): Duration of Trials
Table 14.17 Geographical Clinical Trial Analysis (Other Linker based Molecules): Duration of Trials
Table 17.1 ADC Therapeutics: Development Status of Late Stage Candidates
Table 17.2 ADC Therapeutics: Outsourcing Activity for Late Stage Candidates
Table 23.1 ADC Contract Manufacturing Service Providers: Distribution by Year of Establishment
Table 23.2 ADC Contract Manufacturing Service Providers: Distribution by Company Size
Table 23.3 ADC Contract Manufacturing Service Providers: Distribution by Service(s) Offered
Table 23.4 ADC Contract Manufacturing Service Providers: Distribution by Other Service(s) Offered
Table 23.5 ADC Contract Manufacturing Service Providers: Distribution by Scale of Operation
Table 23.6 ADC Contract Manufacturing Service Providers: Distribution by Location of Headquarters
Table 23.7 ADC Contract Manufacturing Service Providers: Distribution by Service(s) Offered and Location of Headquarters
Table 23.8 Recent Expansions: Cumulative Year-wise Trend, 2012-2020
Table 23.9 Recent Expansions: Distribution by Type of Facility Expansion
Table 23.10 Recent Expansions: Distribution by Type of Service(s) Offered
Table 23.11 Recent Expansions: Distribution by Year of Expansion and Type of Service(s) Offered
Table 23.12 Recent Expansions: Distribution by Location of Expanded Facility
Table 23.13 Recent Expansions: Distribution by Scale of Operation
Table 23.14 Recent Expansions: Distribution by Location of Expanded Facility and Scale of Operation
Table 23.15 Most Active Players: Distribution by Number of Expansions
Table 23.16 Partnerships and Collaborations: Cumulative Year-wise Trend, 2012-2020
Table 23.17 Partnerships and Collaborations: Distribution by Type of Partnership
Table 23.18 Most Active Players: Distribution by Number of Partnerships
Table 23.19 Partnerships and Collaborations: Regional Distribution
Table 23.20 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 23.21 ADC Therapeutics: Distribution by Cost of Raw Material Required for Clinical Stage Manufacturing (%)
Table 23.22 Value Chain Analysis: Distribution by Cost
Table 23.23 Capacity Analysis: Distribution by Company Size
Table 23.24 Capacity Analysis: Distribution by Location of Headquarters
Table 23.25 Capacity Analysis: Distribution by Location of Manufacturing Facilities (Country-wise)
Table 23.26 Capacity Analysis: Distribution by Location of Manufacturing Facilities (Continent-wise)
Table 23.27 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Phase of Development
Table 23.28 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Target Indication
Table 23.29 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Type of Solid Tumor
Table 23.30 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Type of Hematological Malignancies
Table 23.31 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Target Antigen
Table 23.32 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Antibody Origin
Table 23.33 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Antibody Isotype
Table 23.34 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Type of Payload / Warhead
Table 23.35 ADC Therapeutics (Approved / Clinical Pipeline): Distribution by Type of Linker
Table 23.36 ADC Therapeutics (Preclinical Pipeline): Distribution by Key Technology Providers
Table 23.37 Clinical Trial Analysis: Distribution by Trial Registration Year
Table 23.38 Clinical Trial Analysis: Distribution by Trial Phase
Table 23.39 Clinical Trial Analysis: Distribution by Trial Status
Table 23.40 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 23.41 Clinical Trial Analysis: Distribution by Type of Cancer
Table 23.42 Most Active Industry Players: Distribution by Number of Registered Studies
Table 23.43 Geographical Clinical Trial Analysis: Distribution by Number of Trials
Table 23.44 Geographical Clinical Trial Analysis: Distribution by Enrolled Patient Population
Table 23.45 Geographical Clinical Trial Analysis: Distribution by Antibody Isotype
Table 23.46 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Trial Phase
Table 23.47 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Trial Status
Table 23.48 Geographical Clinical Trial Analysis (IgG1 based Molecules): Distribution by Enrolled Patient Population
Table 23.49 Geographical Clinical Trial Analysis (IgG2 based Molecules): Distribution by Trial Phase
Table 23.50 Geographical Clinical Trial Analysis (IgG2 based Molecules): Distribution by Trial Status
Table 23.51 Geographical Clinical Trial Analysis (IgG2 based Molecules): Distribution by Enrolled Patient Population
Table 23.52 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Trial Phase
Table 23.53 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Trial Status
Table 23.54 Geographical Clinical Trial Analysis (IgG4 based Molecules): Distribution by Enrolled Patient Population
Table 23.55 Geographical Clinical Trial Analysis: Distribution by Payload Type
Table 23.56 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Trial Phase
Table 23.57 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Trial Status
Table 23.58 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Enrolled Patient Population
Table 23.59 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Trial Phase
Table 23.60 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Trial Status
Table 23.61 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Enrolled Patient Population
Table 23.62 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Trial Phase
Table 23.63 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Trial Status
Table 23.64 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Enrolled Patient Population
Table 23.65 Geographical Clinical Trial Analysis (PBD based Molecules): Distribution by Trial Phase
Table 23.66 Geographical Clinical Trial Analysis (PBD based Molecules): Distribution by Trial Status
Table 23.67 Geographical Clinical Trial Analysis (PBD based Molecules): Distribution by Enrolled Patient Population
Table 23.68 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Trial Phase
Table 23.69 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Trial Status
Table 23.70 Geographical Clinical Trial Analysis (Camptothecin based Molecules): Distribution by Enrolled Patient Population
Table 23.71 Geographical Clinical Trial Analysis (Pyranoindolizinoquinoline based Molecules): Distribution by Trial Phase
Table 23.72 Geographical Clinical Trial Analysis (Pyranoindolizinoquinoline based Molecules): Distribution by Trial Status
Table 23.73 Geographical Clinical Trial Analysis (Pyranoindolizinoquinoline based Molecules): Distribution by Enrolled Patient Population
Table 23.74 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Trial Phase
Table 23.75 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Trial Status
Table 23.76 Geographical Clinical Trial Analysis (Other Payload based Molecules): Distribution by Enrolled Patient Population
Table 23.77 ADC Therapeutics: Geographical Clinical Trial Distribution by Linker Type
Table 23.78 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Trial Phase
Table 23.79 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Trial Status
Table 23.80 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Enrolled Patient Population
Table 23.81 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Trial Phase
Table 23.82 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Trial Status
Table 23.83 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Enrolled Patient Population
Table 23.84 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Trial Phase
Table 23.85 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Trial Status
Table 23.86 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Enrolled Patient Population
Table 23.87 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Trial Phase
Table 23.88 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Trial Status
Table 23.89 Geographical Clinical Trial Analysis (Peptide Linker based Molecules): Distribution by Enrolled Patient Population
Table 23.90 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Trial Phase
Table 23.91 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Trial Status
Table 23.92 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Enrolled Patient Population
Table 23.93 Geographical Clinical Trial Analysis (MC based Molecules): Distribution by Trial Phase
Table 23.94 Geographical Clinical Trial Analysis (MC based Molecules): Distribution by Trial Status
Table 23.95 Geographical Clinical Trial Analysis (MC based Molecules): Distribution by Enrolled Patient Population
Table 23.96 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Trial Phase
Table 23.97 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Trial Status
Table 23.98 Geographical Clinical Trial Analysis (Other Linker based Molecules): Distribution by Enrolled Patient Population
Table 23.99 Global Demand for ADC Therapeutics (in kgs), 2020-2030
Table 23.100 Global Demand for ADC Therapeutics: Distribution by Scale of Operation, 2020-2030 (in kgs)
Table 23.101 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Cancer, 2020-2030 (in kgs)
Table 23.102 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Origin, 2020-2030 (in kgs)
Table 23.103 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Antibody Isotype, 2020-2030 (in kgs)
Table 23.104 Global Commercial Demand for ADC Therapeutics: Distribution by Payload Type, 2020-2030 (in kgs)
Table 23.105 Global Commercial Demand for ADC Therapeutics: Distribution by Linker Type, 2020-2030 (in kgs)
Table 23.106 Global Clinical Demand for ADC Therapeutics: Distribution by Phase of Development, 2020-2030 (in kgs)
Table 23.107 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Cancer, 2020-2030 (in kgs)
Table 23.108 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Origin, 2020-2030 (in kgs)
Table 23.109 Global Clinical Demand for ADC Therapeutics: Distribution by Payload Type, 2020-2030 (in kgs)
Table 23.110 Global Clinical Demand for ADC Therapeutics: Distribution by Linker Type, 2020-2030 (in kgs)
Table 23.111 Global Clinical Demand for ADC Therapeutics: Distribution by Key Geographical Regions, 2020-2030 (in kgs)
Table 23.112 ADC Therapeutics: Demand and Supply Scenario, 2020 - 2030
Table 23.113 Regional Capability Assessment: North America
Table 23.114 Regional Capability Assessment: Europe
Table 23.115 Regional Capability Assessment: Asia-Pacific
Table 23.116 Global ADC Therapeutics Market, 2020-2030 (USD Billion)
Table 23.117 ADC Therapeutics Market: Relative Cost of Manufacturing by Type of Component Manufacturing
Table 23.118 ADC Contract Manufacturing Market, 2020-2030: Distribution by Type of Component Manufacturing, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.119 ADC Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.120 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Type of Component Manufacturing, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.121 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Type of Cancer, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.122 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Antibody Origin, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.123 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Antibody Isotype, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.124 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Payload Type, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.125 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Linker Type, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.126 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Distribution by Key Geographical Regions, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.127 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Share of North America, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.128 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Share of EU5, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.129 ADC Contract Manufacturing Market for Commercial Products, 2020-2030: Share of Rest of the World, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.130 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Type of Component Manufacturing, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.131 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Type of Cancer, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.132 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Antibody Origin, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.133 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Antibody Isotype, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.134 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Payload Type, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.135 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Linker Type, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.136 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Distribution by Key Geographical Regions, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.137 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Share of North America, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.138 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Share of Europe, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.139 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Share of Asia-Pacific, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.140 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Share of MENA, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.141 ADC Contract Manufacturing Market for Clinical Products, 2020-2030: Share of Latin America, Conservative, Base and Optimistic Scenarios, (USD Million)
Table 23.142 ADC Contract Manufacturing Market: Conservative, Base and Optimistic Scenario, 2020, 2025 and 2030 (USD Billion)

List Of Company

The following companies and organizations have been mentioned in the report.

  1. 3P Biopharmaceuticals
  2. AB SCiex
  3. AbbVie
  4. AbbVie Contract Manufacturing
  5. AbGenomics International
  6. Advanced BioScience Laboratories (ABL)
  7. ABL Bio
  8. Abzena
  9. ACES Pharma
  10. Adagene
  11. ADC Biotechnology
  12. ADC Therapeutics
  13. Aenova
  14. Affinity Life Sciences
  15. AGC Biologics
  16. Agno Pharma 
  17. Ajinomoto Bio-Pharma Services
  18. ALB Technology
  19. Albany Molecular Research (AMRI)
  20. Alcami
  21. Aldevron
  22. Algeta
  23. Alkermes Contract Pharma Services
  24. Allele Biotechnology & Pharmaceuticals
  25. Allergan
  26. Almac
  27. Alphora Research
  28. Alteogen
  29. Alvotech
  30. Ambrx
  31. Amgen
  32. AMPAC Fine Chemicals
  33. Angiex
  34. Antibodies Incorporated
  35. Antibody Production Services (division of Life Science Group)
  36. Aptuit
  37. Arabio
  38. Arch Pharmalabs
  39. Ardena
  40. Asana BioSciences
  41. Ash Stevens
  42. Aspen Oss
  43. Aspyrian Therapeutics
  44. Astellas Pharma
  45. AstraZeneca
  46. Asymchem Laboratories 
  47. AutekBio
  48. Avacta
  49. Avanthera
  50. Avid Bioservices
  51. Axcellerate Pharma
  52. Batavia Biosciences
  53. Baxter BioPharma Solutions
  54. Bayer
  55. BeiGene
  56. Beth Israel Deaconess Medical Center
  57. BIBITEC
  58. Binex
  59. BioAtla
  60. BioInvent International
  61. Biomay
  62. BioMed Valley Discoveries
  63. Biosynergy (Europe)
  64. Bio-Synthesis
  65. BioTechnique
  66. Biotecnol 
  67. Biotest
  68. Bio-Thera Solutions
  69. BioVectra
  70. Biovian
  71. BioVolutions
  72. BioWa
  73. BlinkBio
  74. Bliss Biopharamceutical
  75. BOC Sciences
  76. Boehringer Ingelheim BioXcellence 
  77. Bolt Biotherapeutics
  78. Bristol-Myers Squibb
  79. Bryllan 
  80. BSP Pharmaceuticals
  81. Burrard Pharmaceuticals
  82. Cambrex
  83. Capsugel
  84. CARBOGEN AMCIS
  85. Catalent Pharma Solutions
  86. Celgene
  87. Cell Culture Company
  88. Cellerant Therapeutics
  89. CellMosaic 
  90. Celltrion
  91. Celon Labs
  92. Celonic
  93. Centrose
  94. Cerbios-Pharma
  95. ChemCon
  96. ChemPartner
  97. ChemSun Pharmaceutical
  98. Chugai Pharmaceuticals
  99. CinnaGen 
  100. CMAB Biopharma
  101. CMC Biologics
  102. Cobra Biologics
  103. Coldstream Laboratories 
  104. Concortis Biosystems 
  105. Consort Medical 
  106. CordenPharma
  107. Creative Biolabs
  108. CSPC Pharmaceutical
  109. CureMeta
  110. CytomX Therapeutics
  111. Cytopharma 
  112. Cytovance Biologics
  113. Daiichi Sankyo
  114. Dalton Pharma Services
  115. Debiopharm
  116. Diatec Monoclonals
  117. DM Bio
  118. Dorizoe Lifesciences
  119. Dottikon Exclusive Synthesis 
  120. Dr. Reddy's Custom Pharmaceutical Services
  121. EirGen Pharma 
  122. EirGenix
  123. Eisai
  124. EMD Serono
  125. Emergent BioSolutions
  126. Esperance Pharmaceuticals
  127. Etinpro
  128. EuBiologics
  129. Eurofins CDMO
  130. Eurogentec
  131. Evonik 
  132. Excella
  133. Exelixis
  134. Farmabios 
  135. Farmhispania Group 
  136. Fermion
  137. FineTech Pharmaceuticals
  138. Flamma 
  139. Formation Biologics
  140. Formex 
  141. Formosa Laboratories
  142. For‐Robin
  143. Fortis Therapeutics
  144. Fosun Pharma
  145. Fresenius Kabi
  146. Fudan-Zhangjiang Bio-Pharmaceutical
  147. FUJIFILM Diosynth Biotechnologies
  148. GamaMabs Pharma
  149. GEA Pharma Systems
  150. Genentech
  151. Genmab
  152. GENTEC Pharmaceutical Group
  153. German Cancer Research Center (DKFZ)
  154. GlaxoSmithKline
  155. Glenmark
  156. Goodwin Biotechnology
  157. GP Pharm
  158. GSK
  159. GT Biopharma
  160. GTP Technology
  161. HALIX 
  162. Hangzhou DAC Biotech
  163. Heidelberg Pharma
  164. Helsinn Advanced Synthesis
  165. Heraeus
  166. Hovione 
  167. iBIOSOURCE
  168. Iconic Therapeutics
  169. ICROM
  170. Idifarma
  171. IDT Australia
  172. IDT Biologika
  173. Igenica Biotherapeutics
  174. Iksuda Therapeutics
  175. ImmunoBiochem
  176. ImmunoGen
  177. Immunomedics
  178. Indena
  179. Innate Pharma
  180. Inno Biologics 
  181. Intas
  182. Intellect Neurosciences
  183. iProgen Biotech
  184. JHL Biotech
  185. Jiangsu Hengrui Medicine
  186. Johns Hopkins University
  187. Johnson Matthey Pharma Services
  188. KBI Biopharma
  189. Kemwell Biopharma
  190. Klus Pharma
  191. Kodiak
  192. KUBio (a manufacturing unit of GE Healthcare)
  193. Kyongbo Pharmaceutical 
  194. Labochim 
  195. LakePharma
  196. LAMPIRE Biological Laboratories
  197. Laureate Biopharmaceutical Services
  198. LegoChem Biosciences
  199. Leica Biosystems
  200. Levena Biopharma
  201. LFB Biomanufacturing
  202. Light Chain Bioscience 
  203. LinXis
  204. Lonza
  205. MAB Discovery
  206. Mabion
  207. MabPlex
  208. MabVax
  209. Mab-Venture Biopharma
  210. Mac-Chem
  211. MacroGenics 
  212. Magenta Therapeutics
  213. Magle Chemoswed
  214. Maine Biotechnology Services
  215. MassBiologics
  216. Max Delbrück Center for Molecular Medicine
  217. Mayne Pharma 
  218. MediaPharma
  219. Medichem
  220. MedImmune
  221. Medix Biochemica
  222. Menarini
  223. Menarini Biotech
  224. Merck
  225. Merck Millipore
  226. Meridian Life Science
  227. Mersana Therapeutics
  228. Metrics Contract Services
  229. MilliporeSigma
  230. Minafin Group
  231. Miracogen
  232. Mitsubishi Tanabe Pharma
  233. Mologic
  234. MorphoSys
  235. Morphotek 
  236. MuseChem
  237. Mycenax Biotech
  238. NanoValent Pharmaceuticals
  239. National Cancer Institute
  240. National Institutes of Health
  241. Navrogen
  242. NBE-Therapeutics
  243. NerPharma
  244. Nerviano Medical Sciences
  245. Nitto Avecia Pharma Services
  246. NJ Bio
  247. Nordic Nanovector
  248. Normon
  249. Northway Biotechpharma
  250. Novasep
  251. NovoCodex Biopharmaceuticals
  252. OBI Pharma
  253. OGD2 Pharma
  254. Ology Bioservices
  255. Olon
  256. Oncolinx
  257. Oncomatryx Biopharma
  258. Oncotec Pharma
  259. Orano Med
  260. OsoBio (a subsidiary of AMRI)
  261. Oxford BioTherapeutics
  262. Particle Sciences 
  263. Patheon
  264. Paul Scherrer Institute
  265. PCI Pharma Services
  266. Pensatech Pharma
  267. Pfanstiehl 
  268. Pfizer
  269. Pfizer CentreOne
  270. Pharmaceutics International
  271. PharmaMar
  272. Pharmascience
  273. Pharmedartis
  274. Philochem
  275. Pierre Fabre
  276. Piramal Pharma Solutions
  277. PMI BioPharma Solutions
  278. Polymun Scientific
  279. PrasFarma
  280. Praxis Pharmaceutical
  281. Premas Biotech
  282. ProBioGen
  283. Procos 
  284. ProJect Pharmaceutics
  285. ProteoGenix
  286. PX'Therapeutics
  287. Quality Assistance
  288. Quotient Sciences
  289. Radimmune Therapeutics
  290. Rakuten Medical
  291. Recipharm
  292. Redwood Bioscience
  293. Regeneron Pharmaceuticals
  294. Regis Technologies
  295. RemeGen
  296. Rentschler Biopharma
  297. Research Corporation Technologies
  298. Richman Chemical
  299. Richter-Helm BioLogics
  300. Roche
  301. SAFC 
  302. Saltigo 
  303. Samsung BioLogics
  304. Samsung Medical Center
  305. Sanofi Active Ingredient Solutions
  306. Sanofi 
  307. Sartorius Stedim Biotech
  308. ScinoPharm
  309. SDIX
  310. Seattle Genetics
  311. Servier
  312. Shanghai Jiaolian Drug Development
  313. Shanghai Pharmaceuticals 
  314. Shenogen Pharma
  315. Siam Bioscience
  316. Siamab Therapeutics
  317. Siegfried 
  318. Somatek 
  319. Sorrento Therapeutics
  320. Spirogen 
  321. STA Pharmaceutical 
  322. Stason Pharmaceuticals
  323. Stemcentrx
  324. Sutro Biopharma
  325. Symbiosis Pharmaceutical Services
  326. Synaffix
  327. Syndivia
  328. Syngene
  329. Synthon
  330. Symphogen 
  331. Takara Bio
  332. Takeda Oncology
  333. TBD-Biodiscovery
  334. Telix Pharmaceuticals
  335. Teresi Pharmaceuticals
  336. Teva api
  337. The Chemistry Research Solution
  338. The Hong Kong Institute of Biotechnology
  339. The Native Antigen Company
  340. Therapure Biopharma
  341. Thermo Fisher Scientific
  342. Tot Biopharm
  343. Toyobo Biologics 
  344. Transporin
  345. TRIANNI
  346. TRIO Pharmaceuticals
  347. Triphase Accelerator
  348. Tsinghua University Innovation Center for Immune Therapy
  349. TUBE Pharma 
  350. University Medical Center Groningen
  351. University of California
  352. University of California, San Francisco
  353. University of Freiburg
  354. UPM Pharmaceuticals
  355. Uquifa
  356. Vaccinex
  357. VelosBio
  358. Vibalogics
  359. Visterra
  360. VUAB Pharma
  361. Waisman Biomanufacturing
  362. Waterstone Pharmaceuticals
  363. WHP Engineering
  364. WuXi AppTec 
  365. WuXi Biologics
  366. Wyeth-Ayerst Laboratories
  367. Xintela
  368. Y-Biologics
  369. Yale School of Medicine
  370. Zhejiang Hisun Pharmaceutical
  371. Zhejiang Teruisi Pharmaceutical 
  372. Zymeworks

 

 

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com